Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thiotepa + melphalan
- Development stage
- Phase 1
- Lead developer
- Adienne S.r.l. S.U.
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A high-dose chemotherapy combination regimen used primarily as conditioning treatment before autologous or allogeneic hematopoietic stem cell transplantation (HSCT). This combination is particularly valuable for pediatric solid tumors (including CNS tumors) and hematological malignancies. Thiotepa can cross the blood-brain barrier, making it effective for CNS penetration, while melphalan provides additional alkylating activity. The combination is administered intravenously, typically in cycles with specific dosing schedules to maximize efficacy while managing toxicity.
- Other names
- thiotepa and melphalanthiotepa/melphalanHD-TM
02
Targets
DNA
Beyond the preview
Go deeper on thiotepa + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thiotepa + melphalan.